A question of Big Pharma and their agenda and how much it really impacts new research
If its not patentable, already out of commercial license and does not have many side effects then why the heck would we fund it, when we can sell you something 10x more expensive instead.
From the comments
This is what happens when governments are taken over by the corporate sector. If there is no profit in it, and in this case the patent is off aspirin, then there is no research, despite the billions in healthcare cost savings and the societal benefits. That doesn't matter - it's all about enriching the corporate class, even if it harms society. How perverse have we become??
http://www.cbc.ca/news/health/can-aspirin-treat-breast-cancer-why-aren-t-we-trying-to-find-out-1.2714640With no lucrative patent to be had, drug companies are reluctant to fund costly trials
When something belongs to everyone, like the sun, or the air, it has no market value. This is also true for the bark of the willow tree.
If no one owns it, then no one can sell it. And if no one can sell it, then who will invest the money to find out if it can treat breast cancer and save thousands of lives?
This is the dilemma confronting Dr. Michelle Holmes, a Harvard University researcher who believes that she has observed a chemical from the willow tree that looks to be doubling the survival rate from breast cancer.
The chemical is salicylic acid, modified into acetylsalicylic acid, pressed into a familiar white tablet and sold for more than a century as Aspirin.
Of course, some companies, notably Bayer, did make a fortune from the sale of Aspirin over the decades.
But its patent has long expired, which means its coffer-filling, block-buster days are over. And that's a problem for researchers who believe this humble drug might be harbouring unrecognized cancer-fighting properties.
Using data from the long-running Nurses' Health Study, Dr. Holmes identified more than 4,000 women with breast cancer, who had already undergone normal treatment, including surgery, chemotherapy and radiation.
She compared the death rate with the amount of Aspirin they had taken for other reasons — such as for pain, or the prevention of heart disease — and found that women who reported taking Aspirin were 50 per cent less likely to die from their cancer than the women who did not take Aspirin or its generic form, ASA.
Continues in article.